三生制药(01530)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01530 三生制药

休市中 04-24 16:08:27

22.760

+0.620

+2.80%

最高22.980	最低21.040	成交量5,098万
今开22.100	昨收22.140	日振幅8.76%
总市值577.65亿	流通市值577.65亿	总股本25.38亿
成交额11.34亿	换手率2.01%	流通股本25.38亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01530","market":"HK","secType":"STK","nameCN":"三生制药","latestPrice":22.76,"timestamp":1777018107003,"preClose":22.14,"halted":0,"volume":50983308,"delay":0,"changeRate":0.02800361336946707,"floatShares":2538000000,"shares":2538000000,"eps":3.9313874915769516,"marketStatus":"休市中","change":0.62,"latestTime":"04-24 16:08:27","open":22.1,"high":22.98,"low":21.04,"amount":1133920425,"amplitude":0.087624,"askPrice":22.76,"askSize":569000,"bidPrice":22.74,"bidSize":24500,"shortable":3,"etf":0,"ttmEps":3.9313874915769516,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777253400000},"marketStatusCode":7,"adr":0,"listingDate":1433952000000,"exchange":"SEHK","adjPreClose":22.14,"dividendRate":0.011249,"openAndCloseTimeList":[[1776994200000,1777003200000],[1777006800000,1777017600000]],"volumeRatio":1.165416733553311,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01530","defaultTab":"news","newsList":[{"id":"2629819536","title":"【券商聚焦】招商证券维持三生制药(01530)“强烈推荐”评级 指公司价值显著低估","url":"https://stock-news.laohu8.com/highlight/detail?id=2629819536","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629819536?lang=zh_cn&edition=full","pubTime":"2026-04-24 16:37","pubTimestamp":1777019869,"startTime":"0","endTime":"0","summary":"剔除授权收入后，核心生物药品销售额因集采和医保政策影响同比下降10.3%至80.1亿元。2025年公司与辉瑞达成重磅授权协议，是公司价值重估的核心催化剂。2025年辉瑞完成交割后公布7项临床方案，2026年新增多项方案，目前已登记9项临床试验。招商证券维持“强烈推荐”评级。当前公司市值未体现707分子作为下一代IO基石药物的潜力，海外合作伙伴辉瑞高效推进临床试验，707分子价值有望持续扩大、兑现。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1979891","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06099","01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629023400","title":"港股异动 | 创新药概念全线走低 油价上涨压制降息空间 市场关注创新药投融资前景","url":"https://stock-news.laohu8.com/highlight/detail?id=2629023400","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629023400?lang=zh_cn&edition=full","pubTime":"2026-04-23 13:59","pubTimestamp":1776923941,"startTime":"0","endTime":"0","summary":"消息面上，地缘局势不确定性持续存在，油价上涨推升通胀预期压制降息空间。招商银行研究院发布报告称，2025年，受到全球地缘政治压力以及美联储降息节奏的影响，全球创新药融资同比下降7.1%，但Q3的融资额已恢复8%的正增长。2026年如果美伊战争影响逐渐消除，美联储仍能持续降息，创新药投融资有望持续恢复。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432508.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["USL","HK0000165453.HKD","LU2097828714.EUR","LU2488822045.USD","USOI","LU2328871848.SGD","BK4585","03692","LU2242644610.SGD","BK1583","DRLL","BK1191","BWET","IEO","LU2097828557.USD","DIG","01801","GUSH","LU0455707207.USD","06978","BK4570","VDE","ERX","UGA","IXC","LU2097828805.USD","DBO","LU2097828474.EUR","VXUS","BK1589","BK1593","OILT","159992","OIH","DBE","01530","DRIP","BK1161","DUG","LU0502904849.HKD","DBC","LU1969619763.USD","LU2097828631.EUR","09995","USE","BK1574","OILK","PXJ","OILU","BNO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628719049","title":"招银国际：医疗板块风险偏好有温和的修复 推荐翰森制药(03692)等6股","url":"https://stock-news.laohu8.com/highlight/detail?id=2628719049","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628719049?lang=zh_cn&edition=full","pubTime":"2026-04-20 11:36","pubTimestamp":1776656176,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招银国际发布研报称，MSCI中国医疗指数2026年初至今累计上涨12.3%，跑赢MSCI中国指数13.6%。近期在中国政府工作报告将生物医学列为新兴支柱产业的政策催化下，板块风险偏好有温和的修复。同时，AI制药技术突破与中国创新药出海 BD 的爆发形成双重共振，该行预期产业基本面加速向好。招商国际给予该6只股份“买入”的投资评级，目标价分别为46.41港元、113.86港元、34.87港元、10.34港元、82港元及35.46美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430519.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0502904849.HKD","BK1574","LU0455707207.USD","HK0000165453.HKD","BK1589","SG9999014674.SGD","BK1593","BK1191","LU2242644610.SGD","02268","LU2328871848.SGD","01801","03692","BK1161","LU2097828557.USD","LU2097828631.EUR","BK1583","LU2097828474.EUR","01530","LU2488822045.USD","LU2097828714.EUR","BK1141","LU2097828805.USD","01167","159891","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121984026","title":"异动解读 | 三生制药盘中大涨5.30%，新药获批临床及低估值成催化剂","url":"https://stock-news.laohu8.com/highlight/detail?id=1121984026","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121984026?lang=zh_cn&edition=full","pubTime":"2026-04-17 09:33","pubTimestamp":1776389624,"startTime":"0","endTime":"0","summary":"三生制药今日盘中股价大幅上涨5.30%，引起了市场的广泛关注。消息面上，公司旗下在研新药SSGJ-707（PF-08634404）近日获得国家药品监督管理局药品审评中心批准两项重磅适应症的临床试验，分别用于联合化疗一线治疗转化型小细胞肺癌，以及单药或联合治疗局部晚期或转移性肾细胞癌。这一研发进展被视为公司创新管线的重要突破，增强了市场对其未来增长潜力的信心。此外，投行摩根士丹利维持了对该公司的“增持”评级，并给出目标价。同时，公司当前估值水平较低，静态市盈率约6.74倍，叠加创新药物的持续推进，共同推动了市场做多情绪。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627405785","title":"港股三生制药午后一度涨超9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627405785","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627405785?lang=zh_cn&edition=full","pubTime":"2026-04-15 14:41","pubTimestamp":1776235315,"startTime":"0","endTime":"0","summary":"每经AI快讯，4月15日，三生制药(01530.HK)午后一度涨超9%，截至发稿涨7.2%，报24.7港元，成交额13.03亿港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604153705816241.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604153705816241.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","BK1161","HK0000165453.HKD","VXUS","01530","BK4585","BK1583","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627540590","title":"港股异动 | 三生制药(01530)午后涨超9% SSGJ-707国内获批肺癌、肾癌临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2627540590","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627540590?lang=zh_cn&edition=full","pubTime":"2026-04-15 14:35","pubTimestamp":1776234920,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，三生制药午后涨超9%，截至发稿，涨7.2%，报24.7港元，成交额13.03亿港元。消息面上，4月7日，CDE官网显示，辉瑞申报的1类新药PF-08634404正式获批两项重磅适应症临床：联合化疗一线治疗转化型小细胞肺癌，以及单药/联合治疗局部晚期或转移性肾细胞癌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428720.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","01530","HK0000165453.HKD","VXUS","BK1161","BK1593","BK1583","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627496144","title":"大摩：降三生制药(01530)目标价至34港元 评级“增持”","url":"https://stock-news.laohu8.com/highlight/detail?id=2627496144","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627496144?lang=zh_cn&edition=full","pubTime":"2026-04-14 11:26","pubTimestamp":1776137216,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，大摩发布研报称，纳入三生制药(01530)2025年业绩报，下调三生制药核心商业化产品TPIAO销售预测及里程碑付款，主要受美元兑人民币贬值影响，将公司2026至2028年收入预测分别下调5%、7%及6%。亦根据最新趋势调低产品毛利率，并调整营运开支比率。将同期每股盈利预测分别下调8.3%、14.5%及12.4%。目标价由38港元降至34港元。评级增持。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428134.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174752895","title":"一周港股牛熊榜 | 迅策周涨56%、滴普科技飙52%；稳定币牌照催化，国泰君安国际升31%","url":"https://stock-news.laohu8.com/highlight/detail?id=1174752895","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174752895?lang=zh_cn&edition=full","pubTime":"2026-04-10 16:47","pubTimestamp":1775810821,"startTime":"0","endTime":"0","summary":"近期港股市场整体活跃，多只中小市值个股创阶段新高，而怡俊集团控股亦成为资金关注对象之一。TCL电子本周升幅29.85%消息面上，公司近期发布 2025年全年业绩，业绩表现强劲，成为股价上涨的重要催化。业绩公布后，市场反应积极，股价一度 大涨超过10%。","market":"hk","thumbnail":"https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"324431b18d184842b2237adf08e51534","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03033","HSTECH","02656","HSI","03668","02889","03317","01384","09903","03625","01530","02565","01788"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2626677051","title":"财报之后，南向资金能否撑起三生制药(01530)的股价反弹？","url":"https://stock-news.laohu8.com/highlight/detail?id=2626677051","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626677051?lang=zh_cn&edition=full","pubTime":"2026-04-10 15:57","pubTimestamp":1775807844,"startTime":"0","endTime":"0","summary":"去年5月20日，三生制药与辉瑞达成了一项交易总额最高逾60亿美元的大型BD交易，并凭借其中高达14亿美元的首付款刷新了国产创新药出海首付款金额的纪录。授权交易达成后，辉瑞还将按30日成交量加权平均价认购了三生制药1亿美元普通股。而近日，这项大型BD交易带来的正面影响映射在了三生制药的年报中。在后续港股创新药牛市带动下，三生制药股价2025年度涨幅高达314.75%，若以年度高点36.8港元计算，公司股价年内最高涨幅则达到了531.22%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427036.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625946383","title":"三生制药发声明：与三生（中国）和宁波三生不存在任何关联","url":"https://stock-news.laohu8.com/highlight/detail?id=2625946383","media":"华夏时报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625946383?lang=zh_cn&edition=full","pubTime":"2026-04-08 19:53","pubTimestamp":1775649180,"startTime":"0","endTime":"0","summary":"在医药行业品牌集中度持续提升、市场主体日益多元的当下，“同名”或“近似名”引发的主体混淆问题逐渐成为行业关注的焦点。近日，三生制药发布官方声明，明确其与“三生（中国）健康产业有限公司”“宁波三生生物科技股份有限公司”不存在任何关联关系，此举既是对市场问询的正面回应，也折射出医药企业在品牌保护与市场区隔上的行业共性需求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604083698247875.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604083698247875.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1593","BK1583","01530","HK0000165453.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179219096","title":"异动解读 | 三生制药盘中大跌6.46%，机构下调盈利预测施压","url":"https://stock-news.laohu8.com/highlight/detail?id=1179219096","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179219096?lang=zh_cn&edition=full","pubTime":"2026-04-08 13:50","pubTimestamp":1775627451,"startTime":"0","endTime":"0","summary":"三生制药今日盘中股价出现大幅下跌，跌幅达6.46%，市场表现引人关注。消息面上，国信证券发布报告指出，三生制药的国内药品销售业务存在一定压力。基于此，该机构小幅下调了公司2026-2027年的盈利预测，并新增了2028年的预测。具体来看，预计2026年至2028年公司归母净利润分别为24.5亿元、26.6亿元和27.9亿元，其中2026年预测较此前值28.8亿元有所下调。这一盈利预期的下调，被认为是导致股价承压下行的重要原因。报告同时也提到，公司的在研药物“707”快速开启了全球3期多中心临床，未来有望成为重磅产品，并因此维持了对公司“优于大市”的评级。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625992019","title":"三生制药(01530)跌超5% 机构指其国内药品销售业务存在一定压力","url":"https://stock-news.laohu8.com/highlight/detail?id=2625992019","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625992019?lang=zh_cn&edition=full","pubTime":"2026-04-08 13:42","pubTimestamp":1775626960,"startTime":"0","endTime":"0","summary":"金吾财讯 | 三生制药(01530)股价逆市走低，截至发稿，报24港元，跌5.44%，成交额10.82亿港元。国信证券表示，基于公司国内药品销售业务存在一定压力，该机构小幅下调2026-27年的盈利预测，并新增2028年盈利预测。预计2026-28年公司归母净利润为24.5/26.6/27.9亿元（26-27年前值为28.8/32.1），同比增长-71.2%/8.9%/4.7%，对应当前股价PE=24.6/22.5/21.5x。公司的707快速开启全球3期多中心临床，有望成为重磅炸弹，维持“优于大市”评级。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210810/Y2E2NzVmYjg0MWU1MjU0NDY3MDY2MjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/Y2E2NzVmYjg0MWU1MjU0NDY3MDY2MjI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1978379","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1593","01530","BK1161","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164437524","title":"三生制药更新3月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1164437524","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164437524?lang=zh_cn&edition=full","pubTime":"2026-04-02 16:36","pubTimestamp":1775118961,"startTime":"0","endTime":"0","summary":"三生制药于2026年4月2日公布截至2026年3月31日的股份变动月报表。公告显示，公司法定注册股本为50,000,000,000股，面值为每股USD0.00001，总额维持USD500,000；报告期内未出现任何增减变动。根据月报披露，三生制药截至3月底已发行股份总数为2,538,005,412股，与上月底保持一致，无新增发行、购回、注销或库藏股活动。截至本月末，公司股本结构维持稳定，月报由公司秘书黎少娟签署。公司公告称已遵守香港联交所上市规则及相关法律法规的要求。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137929411","title":"异动解读 | 三生制药盘中大涨11.22%，因实物分派蔓迪国际股份及行业利好","url":"https://stock-news.laohu8.com/highlight/detail?id=1137929411","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137929411?lang=zh_cn&edition=full","pubTime":"2026-04-01 13:44","pubTimestamp":1775022255,"startTime":"0","endTime":"0","summary":"三生制药(01530)今日盘中股价大幅上涨11.22%，引起了市场的广泛关注。消息面上，三生制药宣布将通过实物分派方式，向合资格股东派发其持有的全部蔓迪国际股份，作为特别股息。公司此前已宣布建议分拆蔓迪国际于联交所主板独立上市，目前持有其87.16%权益。这一举措被市场视为价值释放的积极信号，直接推动了股价上涨。此外，医药行业近期迎来多重催化。数据显示，创新药对外授权交易活跃，2026年AACR年会即将举行，多家中国药企将展示创新药成果，且部分龙头创新药公司已实现盈利。行业整体向好也为三生制药的股价提供了支撑。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624833564","title":"创新药概念股强势走高 乐普生物-B(02157)涨14.79% 机构指板块迎来多重共振","url":"https://stock-news.laohu8.com/highlight/detail?id=2624833564","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624833564?lang=zh_cn&edition=full","pubTime":"2026-04-01 13:19","pubTimestamp":1775020740,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念股强势走高，乐普生物-B 涨14.79%，荣昌生物涨14.41%，欧康维视生物-B涨14.25%，亚盛医药-B涨12.07%，博安生物涨11.41%，诺诚健华涨11.21%，海西新药涨11.19%，三生制药涨10.78%，康诺亚-B涨10.21%。华鑫证券表示，2026年中国创新出海趋势持续强化，同时市场对创新药配置有望回升，维持医药行业“推荐”的评级。创新药迎来重要配置机遇，看好目前处于领先位置的双抗和多抗组合。期待今年年4-6月重磅学术会议带来的中国创新药企重磅研究。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1978033","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1969619763.USD","06855","06955","159992","LU2328871848.SGD","02162","06978","09969","09995","BK1161","HK0000165453.HKD","01530","02157","BK1191","02637","BK1583","BK1593","BK1587","01477","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624315564","title":"中金：维持三生制药(01530)跑赢行业评级 目标价36.5港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2624315564","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624315564?lang=zh_cn&edition=full","pubTime":"2026-04-01 11:35","pubTimestamp":1775014509,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，考虑对外授权收入利润确认节奏，下调三生制药26年净利预测47%至30.24亿元，引入27年净利34.65亿元。中金主要观点如下：2025年业绩基本符合市场预期公司公布2025年业绩：收入176.96亿元，同比增长94%;归母/经调净利润84.82亿元/84.54亿元，同比增长306%/265%，基本符合市场预期。内生收入同比有所下滑根据公告25年确认对外授权收入94.3亿元，该行测算剔除后公司全年实现收入82.7亿元，YoY-9%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423799.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["EWH","01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127457182","title":"三生制药发布2025年业绩：创新研发与全球合作双轮驱动 营收突破百亿大关","url":"https://stock-news.laohu8.com/highlight/detail?id=1127457182","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127457182?lang=zh_cn&edition=full","pubTime":"2026-03-31 20:13","pubTimestamp":1774959194,"startTime":"0","endTime":"0","summary":"三生制药公布2025年度业绩报告，公司凭借创新研发与全球合作两大核心引擎的强劲驱动，年度营收首次突破百亿元人民币大关。这一里程碑式的增长凸显了公司战略布局的有效性，以及在生物医药领域的持续领先优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1593","01530","BK1161","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623630663","title":"港股三生制药盘中一度跌近8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623630663","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623630663?lang=zh_cn&edition=full","pubTime":"2026-03-31 15:06","pubTimestamp":1774940802,"startTime":"0","endTime":"0","summary":"每经AI快讯，3月31日，三生制药(01530.HK)盘中一度跌近8%，截至发稿跌6.75%，报22.64港元，成交额12.08亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603313690333488.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603313690333488.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","BK1593","VXUS","BK4585","BK4588","01530","HK0000165453.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623373124","title":"【券商聚焦】中信证券：基本医保基金收支和结余整体保持稳健","url":"https://stock-news.laohu8.com/highlight/detail?id=2623373124","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623373124?lang=zh_cn&edition=full","pubTime":"2026-03-31 08:59","pubTimestamp":1774918794,"startTime":"0","endTime":"0","summary":"2026年2月医保支出同比增速回升，收支剪刀差有所收窄。该机构预计在医保基金监管力度持续加大，DRG/DIP精细化管理的推动下，2026年全年基金结余率或将延续此前节奏略有提升。医疗健康产业政策改革进入密集期，建议持续关注政策驱动下的医疗健康产业投资机会。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977773","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B543WZ88.USD","LU1115378108.SGD","LU1997245177.USD","HK0000165453.HKD","02196","LU2495084118.USD","LU0348766576.USD","09688","BK1191","LU0348735423.USD","BK1583","LU2488822045.USD","BK1515","06160","BK1147","IE00BPRC5H50.USD","BK1617","LU0405327148.USD","LU0405327494.USD","LU1328615791.USD","06030","02228","BK0276","LU1255011170.USD","01789","LU0307460666.USD","LU2148510915.USD","BK0012","09926","LU1719994722.HKD","LU2476274308.USD","LU1969619763.USD","LU1770034418.SGD","06821","02268","LU0348783233.USD","01099","LU1303224171.USD","02367","LU0634319403.HKD","BK1588","BK1564","LU2399975544.HKD","BK0028","03933","BK1100","01530","BK1593","BK1161","600030"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623496733","title":"三生制药(01530)发布年度业绩 股东应占纯利增加305.8%至84.82亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2623496733","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623496733?lang=zh_cn&edition=full","pubTime":"2026-03-30 22:29","pubTimestamp":1774880949,"startTime":"0","endTime":"0","summary":"智通财经APP讯，三生制药 发布截至2025年12月31日止年度全年业绩，集团收入增加94.3%至人民币176.96亿元。毛利增加108.8%至人民币163.47亿元，毛利率为92.4%。母公司拥有人应占纯利增加305.8%至人民币84.82亿元。末期股息每股25港仙。根据IQVIA，于2025年，按销售额计，特比澳在中国内地血小板减少症治疗市场的份额为60.4%。凭借两种rhEPO产品，二十多年来，本集团一直为中国内地rhEPO市场龙头，于2025年共占39.6%的总市场份额。蔓迪在中国内地防脱发药物市场亦占主导地位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"三生制药(01530)发布年度业绩 股东应占纯利增加305.8%至84.82亿元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","HK0000165453.HKD","BK1583","01530","BK1593"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.3sbio.com","stockEarnings":[{"period":"1week","weight":-0.099},{"period":"1month","weight":0.0188},{"period":"3month","weight":-0.0657},{"period":"6month","weight":-0.1866},{"period":"1year","weight":0.7148},{"period":"ytd","weight":-0.0587}],"compareEarnings":[{"period":"1week","weight":-0.007},{"period":"1month","weight":0.0253},{"period":"3month","weight":-0.0288},{"period":"6month","weight":-0.007},{"period":"1year","weight":0.1857},{"period":"ytd","weight":0.0136}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"3SBio Inc是一家主要从事生物制药产品的开发、生产、市场推广及销售的投资控股公司。该公司的主要产品包括特比澳、益比奥、益赛普、赛普汀等生物药物以及蔓迪、丽美治等小分子药物。该公司还从事为客户提供多种生物药的研发生产以及治疗技术平台服务的合同开发与生产运营（CDMO）业务。该公司的产品主要应用于血小板减少症（CIT）、慢性肾病（CKD）引起的贫血症、治疗化疗引起的贫血症（CIA）、强直性嵴柱炎（AS）及银屑病等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":-0.00666},{"month":2,"riseRate":0.454545,"avgChangeRate":0.00178},{"month":3,"riseRate":0.818182,"avgChangeRate":0.113214},{"month":4,"riseRate":0.454545,"avgChangeRate":-0.012607},{"month":5,"riseRate":0.7,"avgChangeRate":0.109101},{"month":6,"riseRate":0.8,"avgChangeRate":0.036581},{"month":7,"riseRate":0.090909,"avgChangeRate":-0.038254},{"month":8,"riseRate":0.363636,"avgChangeRate":-0.014022},{"month":9,"riseRate":0.636364,"avgChangeRate":0.027455},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.018307},{"month":11,"riseRate":0.727273,"avgChangeRate":0.059913},{"month":12,"riseRate":0.454545,"avgChangeRate":-0.045323}],"exchange":"SEHK","name":"三生制药","nameEN":"3SBIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"三生制药(01530)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供三生制药(01530)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"三生制药,01530,三生制药股票,三生制药股票老虎,三生制药股票老虎国际,三生制药行情,三生制药股票行情,三生制药股价,三生制药股市,三生制药股票价格,三生制药股票交易,三生制药股票购买,三生制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"三生制药(01530)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供三生制药(01530)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}